Barriers and Benefits of Germline Testing in Prostate Cancer Care

29 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
A regional roundtable discussion, moderated by Mark Delworth, MD, The Urology Group, explored the evolving landscape of advanced prostate cancer management, including imaging innovations, treatment sequencing, biomarker integration, and patient-centered decision-making. Dr. Delworth was joined by other practitioners at The Urology Group, including Brian Minnillo, MD; Robert Larke, MD; Brooke Edwards, MD; and Stephen Bennett, MD.

In the first segment, the panel explores the role of germline and somatic genetic testing in managing metastatic castration-sensitive prostate cancer, discussing when and how these tests should be integrated into patient care. They address barriers such as patient reluctance, privacy concerns, and timing of conversations, while emphasizing the importance of genetic counseling and adherence to guideline-based testing.
Categoria
Oncology
Commenta per primo questo video.

Prossimo